Table 2.
Quantitative Analysis of GST-P-Positive and -Negative Foci Larger than 0.1 mm in Diameter
| No. of group | Treatment | No. of foci (No./cm2)*
|
||
|---|---|---|---|---|
| GST-P-Positive | GST-P-Negative† | |||
| Experiment 1 | ||||
| 1 | NDEN+ clofibrate | 9.61 ± 2.82 | 1.21 ± 0.85 | |
| 2 | NDEN+ Wy-14,643 | 8.81 ± 2.65 | 11.74 ± 2.65 | |
| 3 | NDEN alone | 16.15 ± 7.46 | 1.74 ± 1.11 | |
| 4 | No treatment | 0.09 ± 0.21 | 0.00 ± 0.00 | |
| Experiment 2 (26W) | ||||
| 1 | NDEN+ clofibrate | 33.17 ± 5.31 | 10.30 ± 2.10 | |
| 2 | NDEN alone | 41.09 ± 9.84 | 5.69 ± 2.40 | |
| 3 | No treatment | 0.24 ± 0.22 | 0.00 ± 0.00 | |
| Experiment 2 (36W) | ||||
| 1 | NDEN+ clofibrate | 52.02 ± 11.33 | 14.07 ± 2.84 | |
| 2 | NDEN alone | 75.66 ± 10.19 | 9.34 ± 2.72 | |
| 3 | No treatment | 0.25 ± 0.37 | 0.00 ± 0.00 | |
*
Except hepatocellular adenoma and carcinoma.
†
The foci, predominantly amphophilic cell foci, were detected by staining with H&E, and subsequently checked stainability against antibody to GST-P by using the serial sections.